Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evaluating a company built around an implantable sleep-apnea device means combing through pages of clinical data, FDA correspondence, and reimbursement notes. Inspire Medical Systems’ filings can feel like a medical journal, yet missing a single update on trial results or executive trades can sway your view of INSP’s value.
Stock Titan’s AI bridges that gap. Our platform ingests every document the moment it hits EDGAR, from a routine Inspire Medical Systems quarterly earnings report 10-Q filing to the surprise Inspire Medical Systems 8-K material events explained. Instant, plain-English summaries highlight growth in implant procedures, new CMS coverage decisions, and supply-chain disclosures—turning technical paragraphs into clear takeaways.
Use cases investors ask for every quarter are built in:
- Follow Inspire Medical Systems insider trading Form 4 transactions and receive alerts on Inspire Medical Systems Form 4 insider transactions real-time before the market closes.
- Dive into an Inspire Medical Systems annual report 10-K simplified to see unit economics on each neurostimulator sold.
- Compare R&D spending with revenue in our Inspire Medical Systems earnings report filing analysis.
Need context fast? Ask in plain language—“understanding Inspire Medical Systems SEC documents with AI” or “Inspire Medical Systems proxy statement executive compensation”—and the system surfaces the exact table or chart. Whether you’re tracking Inspire Medical Systems executive stock transactions Form 4 or verifying how many centers are implanting the device, you’ll find every disclosure, timestamped and explained simply.
BlackRock, Inc. filed an amended Schedule 13G reporting a passive ownership stake in Inspire Medical Systems (INSP). As of September 30, 2025, BlackRock beneficially owned 3,353,407 shares of INSP, representing 11.3% of the common stock. The filing lists sole voting power over 3,283,122 shares and sole dispositive power over 3,353,407 shares, with no shared voting or dispositive power.
BlackRock certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing notes that iShares Core S&P Small-Cap ETF has an interest in INSP common stock that is more than five percent of the total outstanding shares.
Inspire Medical Systems (INSP) reported an insider transaction by a director. On 10/14/2025, the director acquired 229 shares of common stock at $78.84 per share, received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. After this transaction, the director beneficially owns 3,986 shares, held directly.
Inspire Medical Systems (INSP) director Casey M. Tansey reported an equity award. On 10/14/2025, Tansey acquired 221 shares of common stock at $78.84 per share, received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy.
Following this transaction, Tansey beneficially owned 22,235 shares directly. Additional indirect holdings reported include 500 shares held by The Kimberly Tansey Irrevocable Trust and 500 shares held by The Kylie Tansey Irrevocable Trust.
Inspire Medical Systems (INSP) director Gary L. Ellis reported acquiring 372 shares of common stock on October 14, 2025. The shares were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, at a reported price of $78.84 per share.
Following this transaction, Ellis beneficially owns 6,454 shares, held directly. This filing reflects routine director compensation settled in stock rather than cash.
Inspire Medical Systems (INSP) reported an insider equity award. Director Shelley G. Broader acquired 245 shares of common stock on 10/14/2025 at $78.84 per share. The shares were received in lieu of cash fees under the company's Non-Employee Director Compensation Policy.
After this transaction, Broader’s beneficial ownership stands at 4,367 shares, held directly.
FMR LLC and Abigail P. Johnson filed Amendment No. 4 to a Schedule 13G reporting ownership of common stock of Inspire Medical Systems, Inc. The filing shows an aggregate beneficial ownership of 741,312.10 shares, representing
Citadel and related entities reported ownership stakes in Inspire Medical Systems (INSP). The joint Schedule 13G shows Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each may be deemed to beneficially own 1,379,861 shares representing
Richard Buchholz, Chief Financial Officer and Director of Inspire Medical Systems, Inc. (INSP), reported an insider sale on 08/29/2025 of 11,000 shares of common stock at a price of $93.39 per share. After the sale, Mr. Buchholz beneficially owned 44,867 shares (direct). The filing also discloses indirect holdings of 1,475 shares each held by his daughter and three sons. The Form 4 was signed by an attorney-in-fact on 09/02/2025.
Inspire Medical Systems (INSP) filed a Form 144 notifying a proposed sale of 11,000 common shares through RBC Capital Markets on 08/29/2025 on the NYSE, with an aggregate market value of $1,027,349.00. The filing reports 29,574,316 shares outstanding, so the proposed block represents roughly 0.04% of outstanding shares. All 11,000 shares were acquired by option exercise between 06/30/2019 and 10/09/2020, totaling the same 11,000 shares listed for sale. No securities were sold by the filer in the past three months, and the filer certifies no undisclosed material adverse information.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
